Using MRI to Diagnose Pancreatic Masses
Experimental and Clinical Study of Three-dimensional Magnetic Resonance Elastography to Evaluate Pancreatic Cancer and Interstitial Fibrosis
This study is testing if a special MRI technique can help doctors better understand pancreatic cancer by measuring the stiffness of tumors to improve treatment decisions for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06526442 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize high order three-dimensional magnetic resonance elastography (3D-MRE) to non-invasively measure the stiffness of pancreatic lesions, particularly pancreatic ductal adenocarcinoma (PDAC). By assessing the mechanical properties of the extracellular matrix surrounding PDAC, the study seeks to identify prognostic factors that could aid in risk stratification and treatment decisions. The research focuses on patients with definitive histologic evidence of PDAC and aims to correlate MRE imaging biomarkers with patient outcomes. The goal is to enhance the understanding of tumor biology and improve clinical management of pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with confirmed pancreatic ductal adenocarcinoma and no history of other malignancies.
Not a fit: Patients with tumors smaller than 1.0 cm or those who have undergone preoperative biliary drainage may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better prognostic predictions and more tailored treatment options for patients with pancreatic cancer.
How similar studies have performed: While the application of MRE imaging biomarkers in predicting PDAC prognosis is novel, similar imaging techniques have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. granting of written informed consent 2. age ≥18 years 3. no history of extrapancreatic malignancy 4. no preoperative biliary drainage 5. definitive histologic evidence of PDAC in excisional biopsy 6. with no less than three months of postoperative mortality or six months of follow- up Exclusion Criteria: 1. inability to re-review of tissue specimens 2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection 3. tumor diameters \<1.0 cm 4. withdrawal/dropout during follow-up
Where this trial is running
Shenyang, Liaoning
- Shengjing hospital of china medical university — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Yu Shi, MD.PhD. — Shengjing Hospital
- Study coordinator: Yu Shi, MD.PhD.
- Email: 18940259980@163.com
- Phone: 8618940259980
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.